iBio Inc (IBIO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.73-8.74%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · IBIO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 12.9% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| -88.4% |
Growth built into the price is above our model estimate.
The price assumes 101.3 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
IBIO — litigation filed
Dated 2026-09-14
Regulation FD Disclosure. iBio, Inc. (the “Company”) has updated its corporate presentation. A copy of the updated corporate presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K. The corporate presentation attached as Exhibit 99.1 to this Current Report on Form 8-K includes “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are “forward-looking” rather than historical. Th…
Why it matters: The next trial stage will test repeated dosing after the single-dose study. It can show whether the program keeps moving on plan.
Supportive ifiBio starts the multiple ascending dose part of the Phase 1 trial and reports dosing details.
Worry ifThe trial has not started by the next update, or iBio reports a pause or delay.
Why it matters: iBio reported cash runway into fiscal 2028, but also has a share-sale deal for up to $100 million. New share sales can add funding and dilute owners.
Watch foriBio reports cash runway still into fiscal 2028 and no large new share sales under the Jefferies deal.
Also watch foriBio reports less runway or discloses large share sales under the Jefferies deal.
Why it matters: iBio has no material sales and reported a sharp rise in research spending. The update can show how fast its cash is being used.
Worry ifQuarterly R&D spending rises above $5 million, versus $3.3 million in the March 2026 quarter.
Less concerning ifQuarterly R&D spending is at or below $3.3 million, with the company still advancing its trials.
Why it matters: The reported fat-loss results came from a small NHP study. Human safety and dose results will test if the program can advance.
Watch forA human trial report shows acceptable safety. It supports more dose testing.
Also watch forA trial report shows a serious safety issue, or dosing stops due to a safety concern.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$218 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $855 loss on $10,000 · 8.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,697 loss on $10,000 · 77.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The NHP data showed more fat loss with semaglutide than with semaglutide alone. A human trial would test whether that result can carry over to people.
Supportive ifiBio starts an IBIO-610 first-in-human trial by June 30, 2027, as planned.
Worry ifiBio says the trial start has moved past June 30, 2027, or reports it will not proceed.